Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LB-100 + LY2603618 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LB-100 | LB100|LB 100 | PP2A Inhibitor 2 | LB-100 is a small molecule that inhibits PP2A activity, resulting in increased sensitivity of tumor cells to DNA damaging agents, including chemotherapy and radiotherapy (PMID: 25376608, PMID: 31935881, PMID: 30679389, PMID: 32342332). | |
LY2603618 | LY-2603618|Rabusertib | CHK1 Inhibitor 18 | Rabusertib (LY2603618) is a small molecule that inhibits CHK1, which may lead to disruption of DNA synthesis, early mitosis, and apoptosis, and may increase tumor cell sensitivity to chemotherapeutics (PMID: 24114124, PMID: 28625637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|